|
Clinical utility of plasma-based digital next-generation sequencing (NGS) in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - Boehringer Ingelheim (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD Oncology |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; MSD; Novartis; Pfizer; Roche; Takeda |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
Jose Miguel Sanchez Torres |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Guardant Health; Veracyte |
Leadership - Biolase; Guardant Health |
Stock and Other Ownership Interests - Biolase; Guardant Health |
Research Funding - Guardant Health |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche |
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche |
|
|
Consulting or Advisory Role - Astellas Oncology; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche |